Patent: 10,588,947

Summary for Patent: 10,588,947

Title:	Ultrapure hypoallergenic solutions of sacrosidase
Abstract:	The invention provides a method for treating a subject who lacks endogenous sucrase activity by orally administering a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration of less than about 10 ng/ml.
Inventor(s):	Reardan; Dayton T. (Shorewood, MN), Seekamp; Christopher (Brookfield, WI)
Assignee:	QOL Medical LLC (Vero Beach, FL)
Application Number:	15/844,184
Patent Claims:	see list of patent claims

Comprehensive analysis of US Patent 10,588,947: sacrosidase oral replacement therapy claims, claim-by-claim scope, and enforceability risks

US10,588,947 centers on oral administration of a glycosylated 513–amino acid sacrosidase (sucrase/glycosidase) protein preparation derived from Saccharomyces, with tight control of papain impurity (and methods intended for congenital sucrase-isomaltase deficiency or subjects lacking endogenous sucrase activity). The claims are structured around three technical pillars: (i) oral dosing for enzyme replacement, (ii) a specific enzyme identity (513 aa glycosylated sacrosidase), and (iii) impurity/specification limits tied to papain removal and measurement methods (SDS-PAGE band-volume ratio and ng/mL ELISA/SDS-PAGE detectability).

High-level claim architecture (what the patent is really claiming)

At a practical enforcement level, the independent claim (claim 1) and its dependent set (claims 2-10) read as a process-and-quality-defined composition claim converted into a method-of-use for treating sucrase deficiency. The novelty is less about “treating sucrase deficiency with sacrosidase orally” and more about locking down a Saccharomyces-derived sacrosidase product with a glycosylated 513 aa primary structure and unusually stringent papain impurity control, including a quantitative SDS-PAGE band volume ratio and orthogonal impurity metrics.

---

What patents protect US 10,588,947’s core concepts (sacrosidase oral therapy, glycosylated 513 aa identity, and low-papain impurity specs)?

Answer: The patent family around US10,588,947 is best understood as overlapping three IP layers: (1) sacrosidase replacement therapy for congenital sucrase-isomaltase deficiency, (2) definition of the active protein identity/sequence features, and (3) quality attributes and impurity limits tied to protease carryover and detectable assay thresholds.

Layer 1: Method-of-use for sucrase deficiency

Claim 1 frames the method as “treating a subject who lacks endogenous sucrase activity” by oral administration of sacrosidase. In enforcement terms, this layer is usually the hardest to treat as new because the therapeutic concept was already commercially established for this indication (historically as an oral enzyme replacement product for congenital sucrase-isomaltase deficiency).

Layer 2: Active identity constraints (513 aa glycosylated sacrosidase)

The claims require:

• “primary structure of the sacrosidase is a 513 amino acid polypeptide”
• “wherein the primary structure … is glycosylated”

This narrows the scope toward a defined molecular identity and post-translational status. In litigation, identity constraints often become the primary battle: whether the accused product’s enzyme matches the claimed sequence length and glycosylation state.

Layer 3: Papain impurity control (the real differentiator)

Claims repeatedly tie scope to the presence/absence of papain as a residual impurity:

• SDS-PAGE band volume ratio of sacrosidase to other proteins comprising papain ≥ 35:1 (claim 1)
• specific band volume subrange: 35-55:1 (claim 2)
• residual papain: <10 ng/mL (claim 3)
• allergic-safety dosing constraint: 2–10 mL/day does not induce allergic reaction (claim 6)
• alternative “no detectable papain” thresholds:
  • <3 ng/mL by ELISA lower limit of quantification 3 ng/mL (claim 8)
  • “no detectable papain by SDS-PAGE of up to about 15 µg of solution” (claim 9)
• activity ranges: ≥7500 IU/mL (claim 5) and 7500–10,000 IU/mL (claim 10)

These constraints create a “quality-defined product” enforcement hook even if generic sacrosidase is known.

---

What are the exact claim boundaries in US 10,588,947 (claim-by-claim scope and narrowing effects)?

Answer: Claims progressively narrow from an independent method claim into tightly specified product attributes and measurable impurity limits. Dependent claims restrict band ratios, assay thresholds, dosage form, dose volume, enzymatic activity, and allergen risk.

Claim 1 (independent): oral treatment + glycosylated 513 aa sacrosidase + papain band ratio

Core limitations:

1. Method: treating a subject lacking endogenous sucrase activity
2. Route: orally administering
3. Composition: “protein composition consisting essentially of sacrosidase”
   • “consisting essentially” is a significant scope limiter allowing small amounts of other components that do not materially affect basic and novel characteristics.
4. Source/processing: not explicitly required in claim 1 (source appears in claim 3: Saccharomyces derived)
5. Impurity specification:
   • “band volume ratio of sacrosidase to other proteins comprising papain of at least about 35:1 by SDS-PAGE of about 20 µg”
6. Protein identity:
   • “primary structure … a 513 amino acid polypeptide”
   • “wherein … is glycosylated”

Enforcement note: The phrase “other proteins comprising papain” is potentially litigable. It implies that the SDS-PAGE band or set of bands associated with papain (or papain-containing impurities) must be identified as “other proteins comprising papain.” Whether an accused product’s SDS-PAGE band assignment qualifies can be a technical dispute.

Claim 2: band ratio tightened to 35–55:1

Adds:

• “band volume ratio … about 35-55:1”

Boundary effect: Infringement requires the accused product to land inside this window, not merely ≥35:1. If a competitor’s profile yields >55:1, they fall outside claim 2 but could still infringe claim 1.

Claim 3: Saccharomyces-derived sacrosidase + residual papain <10 ng/mL

Adds/changes:

• sacrosidase derived from Saccharomyces
• residual papain concentration <10 ng/mL
• retains sacrosidase/papain SDS-PAGE band ratio ≥35:1
• maintains 513 aa glycosylated identity

Boundary effect: This is a dual-specification claim (SDS-PAGE band ratio and ng/mL residual papain). An accused product can meet one metric but fail the other.

Claim 4: administration in a solution

Adds:

• “protein composition is administered in a solution”

Boundary effect: If a competitor markets a lyophilized powder, capsule, or dispersion not as a “solution,” claim 4 may not be met, though claim 1–3 could still be asserted.

Claim 5: enzymatic activity ≥7500 IU/mL

Adds:

• “sacrosidase has an enzyme activity of at least about 7500 IU/ml”

Boundary effect: Activity units introduce assay variability. This claim is still measurable, but outcomes can hinge on method-of-measurement.

Claim 6: daily dose 2–10 mL/day and no allergic reaction

Adds:

• dose volume: “daily dose … about 2-10 mL per day”
• clinical endpoint: “does not induce an allergic reaction in a human patient afflicted with congenital sucrase-isomaltase deficiency.”

Boundary effect: This is a key litigation vulnerability and practical enforcement hurdle. “Does not induce” is a negative clinical outcome dependent on study design, endpoints, observation period, and patient selection. As a patent claim limitation, it can be difficult to prove infringement without robust human evidence or a validated assumption about risk.

Claim 7: sacrosidase contains <3.0 ng/mL papain

Adds:

• tighter ELISA-adjacent constraint (though not tied to a specific assay method in the text of claim 7)

Boundary effect: Strong narrowing on impurity load.

Claim 8: “no detectable papain” with ELISA LOQ 3 ng/mL

Adds:

• “no detectable papain by an enzyme-linked immunosorbant assay having a lower limit of quantification of 3 ng/mL.”

Boundary effect: This converts the prior threshold concept into a method-defined detectability requirement. It ties “detectable” to a specific LOQ parameter, which is typically critical in litigation over whether “no detectable” was properly measured.

Claim 9: “no detectable papain” by SDS-PAGE up to 15 µg

Adds:

• “no detectable papain by SDS-PAGE of up to about 15 µg of said solution.”

Boundary effect: It sets both an assay and a sample mass cap, narrowing the testing method. It also raises the question of what “detectable” means on SDS-PAGE (visual threshold vs densitometry).

Claim 10: enzymatic activity 7500–10,000 IU/mL

Adds:

• activity window: about 7500-10,000 IU/ml

Boundary effect: Similar to claim 2, a window can exclude products outside the upper bound.

---

How strong are the enforceability prospects: obviousness, indefiniteness, and “consisting essentially of” scope?

Answer: US10,588,947’s enforceability is most vulnerable on (i) novelty/obviousness around using sacrosidase to treat sucrase deficiency orally and (ii) enforceable certainty around impurity measurement and “consisting essentially of” boundaries.

1) Obviousness risk: therapy + identity were likely known; differentiator is papain specs

If earlier art disclosed sacrosidase oral therapy and/or Saccharomyces-derived sacrosidase products, the argument for patentability would rest on the specific combination of:

• 513 aa glycosylated sacrosidase identity, plus
• unusually tight papain impurity control,
• and tying those specs to functional treatment.

In typical US litigation dynamics, “optimization of impurities to meet acceptable safety” is a common obviousness theme. The strength of the patentee’s position depends on whether the record shows a non-obvious technical effect tied to the quantified specs (band ratio, ng/mL limits, assay thresholds).

2) Indefiniteness and proof-of-infringement: negative clinical endpoints and assay-based impurities

Claim 6’s “does not induce an allergic reaction” is the most litigation-fragile limitation. Even if the claim is valid, proving infringement often requires:

• clinical datasets
• comparability to the “afflicted with congenital sucrase-isomaltase deficiency” population
• defined timeframe and criteria for “allergic reaction”

Claim 1 also uses “band volume ratio … of sacrosidase to other proteins comprising papain.” SDS-PAGE quantitation can vary with gel conditions, staining, loading normalization, and densitometry algorithm.

3) “Consisting essentially of” narrows but creates an interpretation fight

“Protein composition consisting essentially of sacrosidase” implies:

• sacrosidase is the primary protein
• other proteins can be present if they do not materially affect the basic and novel characteristics

In practice, a defendant can argue that their “other proteins” materially affect the claimed basic/novel characteristics, limiting infringement. The patentee can argue the papain presence/absence and band ratios define the “basic and novel characteristics.”

---

What generic entry risks exist for sucrase-isomaltase deficiency products using sacrosidase?

Answer: The main entry risk for generic or biosimilar-style developers is failing to match the claimed papain impurity specifications under the specific assay conditions. Even if the therapeutic protein is “the same,” failing residual papain thresholds can avoid infringement of claims 1 and 3–10.

Scenario mapping: how a competitor could avoid infringement

• If residual papain is ≥10 ng/mL, they avoid claim 3.
• If the SDS-PAGE sacrosidase:papain band volume ratio is <35:1, they avoid claim 1 and thus the whole dependent chain.
• If sacrosidase activity falls outside 7500–10,000 IU/mL, they may avoid claims 5 and 10.
• If dosing is not delivered as a “solution,” claim 4 is avoided.
• If allergic reaction data is insufficient or does not support claim 6, defendants can target claim 6 for invalidity or non-infringement depending on litigation posture.

Practical consequence

For market entry, a developer would need a formulation and purification platform that reliably meets both SDS-PAGE band ratio and ng/mL papain limits, with reproducibility under the claim’s stated sample load (eg “about 20 µg” for band ratio in claim 1).

---

When does US 10,588,947 lose exclusivity (patent term and timing for challenges)?

Answer: The enforceability window depends on the application filing date and any adjustments, none of which are provided in the prompt. Without the filing date, PTA/terminal disclaimers, or maintenance status, the exclusivity-loss timeline cannot be stated accurately.

---

What is the Orange Book status of US 10,588,947?

Answer: Not determinable from the prompt. Orange Book status requires the specific FDA application number/NDA/BLA listed drug tied to US10,588,947, which is not provided.

---

What patent litigation affects US 10,588,947?

Answer: Not determinable from the prompt. Litigation requires docket records and case captions tied to US10,588,947.

---

Commercial and regulatory impact: what product attributes must a licensor or litigant prove?

Answer: The most probative technical evidence in disputes over US10,588,947 is the measured papain spec and the identity/glycosylation constraints on the sacrosidase protein.

Evidence package likely required for claim 1 and claim 3

• SDS-PAGE experiment establishing:
  • sacrosidase band
  • “other proteins comprising papain” band assignment
  • band volume ratio at “about 20 µg” load
• Protein identity characterization establishing:
  • 513 amino acid primary structure
  • glycosylation confirmation
• Papain quantitation:
  • ELISA yielding residual papain concentration (<10 ng/mL for claim 3)
• For downstream claims:
  • formulation form factor: solution
  • enzymatic activity measurement method yielding IU/mL values
  • human allergy endpoint data for claim 6

---

Key takeaways

• US 10,588,947 is a quality-constrained oral enzyme replacement patent focused on Saccharomyces-derived glycosylated 513 aa sacrosidase with stringent papain impurity controls.
• The claims’ enforceability hinges on assay-defined impurity metrics: SDS-PAGE band-volume ratio (≥35:1, and 35–55:1 window in claim 2) plus ELISA ng/mL thresholds and “no detectable” assay thresholds.
• The strongest practical infringement lever is the papain impurity profile, not the therapeutic indication.
• Claim 6’s “no allergic reaction” limitation is the most litigation-fragile because it is a negative clinical outcome dependent on evidentiary design.

---

FAQs

1) How do SDS-PAGE band volume ratios in US 10,588,947 determine papain impurity presence?
They require a quantified densitometry ratio between a sacrosidase band and “other proteins comprising papain” at a specified loading mass.

2) What residual papain limits are enforced by US 10,588,947?
Claim 3 requires <10 ng/mL; claim 7 requires <3.0 ng/mL; claims 8 and 9 require “no detectable” papain under specified ELISA LOQ or SDS-PAGE sample loading.

3) What does “consisting essentially of sacrosidase” mean for competing formulations?
It permits non-sacrosidase proteins if they do not materially affect the basic and novel characteristics; it also sets up interpretive disputes over which impurities are materially relevant.

4) Can a product avoid claims by changing sacrosidase activity IU/mL?
Yes for activity-window dependent claims: claim 5 uses ≥7500 IU/mL; claim 10 uses about 7500–10,000 IU/mL.

5) What design choice reduces exposure to claim 6?
Avoiding a “solution” presentation does not necessarily avoid claim 6, but claim 6 depends on clinical non-allergy at a specific daily dose range (2–10 mL/day).

---

References (APA)

1. US Patent 10,588,947 (claims provided in prompt).

Details for Patent 10,588,947

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	April 09, 1998		2037-12-15
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772	May 25, 2022		2037-12-15